Document is current

Article History

Received: 15 March 2019

Accepted: 13 December 2019

First Online: 27 December 2019

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: BB receives honoraria for lectures and advisory board contributions from Pfizer, LEO Pharma, Sanofi, ROVI Laboratories and Bayer Pharmaceuticals; RA received research grants from Bayer and Covidien and honoraria from Bayer, Sanofi, Pfizer and Boehringer-Ingelheim; JBW is involved with all the NOAC manufacturers (Bayer, Boehringer, Pfizer, Daiichi and Portola) and took part in the current ASH guideline panel; JD participated in advisory boards or educational activities for Bayer, Boehringer-Ingelheim, Pfizer and Sanofi and is currently chair of the Clinical Endpoint Committee, MARINER trial for Janssen Research and Development; RH is a member of the executive committee for ‘Betrixaban in the acutely medically ill population’ sponsored by Portola and was awarded a grant to University of Calgary by Portola; IE is involved in various advisory boards (Sanofi, Bayer, Pfizer, Bristol Myers Squibb, Shire, Aspen, Leo Pharma and Stago), has received research grants from Sanofi, Leo Pharma and Stago, and gives industry-sponsored lectures in symposia (Sanofi, Bayer, Pfizer, Bristol Myers Squibb, Shire, Aspen, Leo Pharma and Stago); DI and ZZ have no competing interests to report.